---
title: "Descartes-08 in Generalized myasthenia gravis: Expected outcomes of therapy"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Expected outcomes of therapy. Topics: Company statement of sustained benefit after a finite course without chronic dosing; Retreatment if symptoms recur; Treatment goal named in company materials: minimal symptom expression; Ongoing treatment goal: minimal symptoms and treatment-related adverse events, 2026 international consensus; 6 further topics. 11 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

- Clinically meaningful change: A 2-point improvement in the MG-ADL best predicted clinical improvement (correlation with physician impression of change r = 0.70), and anchor-based and distribution-based minimal clinically important difference cut-offs for the QMG were below a change of 3.0.
- Treatment goals: Guidance states that the ongoing goal is to achieve and sustain minimal symptoms and treatment-related adverse events with a patient-acceptable quality of life, and to reassess treatment when these cannot be sustained. A consensus definition of adequately controlled gMG requires an MGFA post-intervention status of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year, an MG-ADL score of 2 or less, no exacerbation in the last year requiring a change in immunosuppressive or rescue therapy, and no or mild adverse events to therapy.
- Effect sizes of targeted therapies: An analysis of 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) estimated QMG reductions beyond placebo and standard of care of -3.63 (95% credible interval -4.43 to -2.77) points for FcRn inhibitors, -2.59 (-3.92 to -1.28) for C5 complement inhibitors, and -2.50 (-5.11 to 0.12) for CD19+ B-cell depletion, and MG-ADL effects of -1.93 (-2.21 to -1.65), -1.84 (-2.48 to -1.19), and -1.91 (-2.97 to -0.84); meaningful differences between classes were not observed. In an Argenx-funded study, intravenous efgartigimod had the lowest number needed to treat versus placebo for 3-point and 5-point QMG reductions and a 5-point MG-ADL reduction, rozanolixizumab had the lowest for a 3-point MG-ADL reduction, and the number needed to harm was similar across treatments. With eculizumab, minimal symptom expression on the MG-ADL was reached by 21.4% of patients versus 1.7% with placebo at REGAIN week 26, and by 22.9% and 27.8% of the eculizumab/eculizumab and placebo/eculizumab groups at extension week 130.
- Company expectations for Descartes-08: The company states that Descartes-08 is being developed with the goal of providing “sustained clinical benefit following a finite course of treatment”, that sustained benefits were observed through 12 months in the phase 2b trial, and that it believes a single course has the potential to transform the MG treatment paradigm. The company states that its cell therapies are designed to be dosed repeatedly like conventional drugs, in an outpatient setting and without pre-treatment chemotherapy, that retreatment is possible if symptoms return, and that achievement of minimal symptom expression over time remains a key treatment goal for physicians.

Source: [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/); [Katzberg et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24810970/); [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/); [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/); [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/); [Smith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550228/); [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/); [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data); [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.7-2"></a>

### Company statement of sustained benefit after a finite course without chronic dosing

> “Unlike currently approved therapies that generally require cyclical dosing to maintain effect, Descartes-08 is being developed with the goal of providing sustained clinical benefit following a finite course of treatment.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

> “Based on efficacy and safety data observed in our clinical trials thus far, we believe our cell therapies have the potential to deliver deep and durable clinical benefit to a broad group of patients with autoimmune diseases after a single course of therapy.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy.”

Source: [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled)

<a id="topic-2.2.2.7-3"></a>

### Retreatment if symptoms recur

> “We believe the combination of sustained symptom improvement, the ability to retreat if symptoms return, and the quality-of-life benefits of outpatient administration without lymphodepleting chemotherapy sets Descartes-08 apart and has the potential to meaningfully change the way MG is treated.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

> “Our cell therapies are designed to be dosed repeatedly like conventional drugs, administered in an outpatient setting and given without pre-treatment chemotherapy required with many conventional cell therapies.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “The favorable safety profile of mRNA cell therapy enables repeat dosing if needed, providing flexibility”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.7-4"></a>

### Treatment goal named in company materials: minimal symptom expression

> “Achievement of minimal symptom expression over time remains a key treatment goal for physicians”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.7-5"></a>

### Ongoing treatment goal: minimal symptoms and treatment-related adverse events, 2026 international consensus

> “The ongoing treatment goal in MG is to work toward, achieve, and sustain minimal symptoms and treatment-related adverse events, with a patient-acceptable quality of life (using validated measures).”
> “In patients with MG, if minimal symptoms, minimal treatment-related adverse events, and patient-acceptable quality of life cannot be sustained, clinicians should reassess treatment and make changes to achieve treatment goals.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.7-6"></a>

### Minimal clinically important difference of the MG-ADL: 2-point improvement

> “Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.”
> “A 2-point improvement in the MG-ADL indicates clinical improvement.”

Source: [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/)

<a id="topic-2.2.2.7-7"></a>

### Minimal clinically important difference of the QMG: anchor-based and distribution-based estimates

> “One anchor-based and 3 distribution-based techniques were used to identify quantitative myasthenia gravis score (QMGS), repetitive nerve stimulation (RNS), and single-fiber electromyography (SFEMG) MCID cut-offs.”
> “MCID cut-offs were below a QMGS change of 3.0.”

Source: [Katzberg et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24810970/)

<a id="topic-2.2.2.7-8"></a>

### Minimal symptom expression attained with eculizumab: REGAIN week 26 and open-label extension week 130

> “At REGAIN week 26, more eculizumab-treated patients achieved ‘minimal symptom expression’ versus placebo [MG-ADL: 21.4% vs 1.7%; difference 19.8%; 95% confidence interval (CI) 8.5, 31.0; p = 0.0007; MG-QOL15: 16.1% vs 1.7%; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069].”
> “At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved ‘minimal symptom expression’ (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531).”

Source: [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)

<a id="topic-2.2.2.7-9"></a>

### Consensus definition of adequately controlled generalized myasthenia gravis

> “Adequately controlled gMG was defined as achieving Myasthenia Gravis Foundation of America Post-Intervention Status classification of clinical stable remission, pharmacologic remission, or minimal manifestations stable for a year; having an MG-ADL score ≤2; experiencing no clinical exacerbations during the last year requiring a change in immunosuppressive therapy or rescue therapy; and having no or mild AE to therapies (100% of experts in agreement or total agreement).”

Source: [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/)

<a id="topic-2.2.2.7-10"></a>

### Expected effect sizes of FcRn inhibitors, C5 inhibitors, and CD19 B-cell depletion on MG-ADL and QMG: 27 placebo-controlled randomized trials

> “Of 4,823 eligible studies, 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) were included that targeted B cells, neonatal Fc receptor (FcRn), complement activity, CD40, and interleukin-6 signaling, as well as immunoglobulin G and broad immunosuppression therapy.”
> “Compared to those treated with placebo and standard of care, QMG scores decreased by an average of -3.63 (95% credible interval -4.43 to -2.77) points more in patients treated with FcRn inhibitors, -2.59 (-3.92 to -1.28) points more in patients treated with C5 complement inhibitors (C5i), and -2.50 (-5.11 to 0.12) points more in patients treated with CD19+ B-cell depletion therapy (BCDT). The MG-ADL treatment effects were -1.93 (-2.21 to -1.65) for FcRn inhibitors, -1.84 (-2.48 to -1.19) for C5i, and -1.91 (-2.97 to -0.84) for CD19+ BCDT.”
> “FcRn inhibitors, C5i, and CD19+ BCDT showed comparable efficacy in terms of QMG and MG-ADL reduction because meaningful differences were not observed between treatment classes.”

Source: [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)

<a id="topic-2.2.2.7-11"></a>

### Number needed to treat for 3-point and 5-point MG-ADL and QMG improvements: analysis funded by Argenx

> “Efgartigimod IV had the lowest NNT versus placebo for achieving a ≥ 3- and ≥ 5-point reduction in QMG, as well as a ≥ 5-point reduction in MG-ADL, whereas rozanolixizumab had the lowest NNT for a ≥ 3-point reduction in MG-ADL. The NNH versus placebo was similar across comparator treatments.”
> “This study was funded by Argenx.”

Source: [Smith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550228/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
